Legato Capital Management LLC Takes $334,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Legato Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 6,040 shares of the specialty pharmaceutical company’s stock, valued at approximately $334,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. raised its holdings in ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Thompson Siegel & Walmsley LLC raised its holdings in ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after purchasing an additional 34,416 shares during the period. Thrivent Financial for Lutherans raised its holdings in ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Mizuho Markets Americas LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter worth $11,670,000. 76.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target on the stock. Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Finally, StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $77.71.

Insider Activity

In other news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares in the company, valued at $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 over the last 90 days. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Trading Down 0.5 %

Shares of ANI Pharmaceuticals stock opened at $58.92 on Friday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -107.13 and a beta of 0.74. The business has a 50-day moving average price of $56.96 and a 200-day moving average price of $58.36. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.